A further understanding of the ALEKSIN pan-IRF inhibition mode and its IRF-independent potential toward STATs (and possibly NF-kB) could provide great potential for its development as a potent multi-IRF inhibitory strategy in the treatment of vascular inflammation and atherosclerosis. The gene discussed is TRIM63; the disease is inflammation.